Product Description
Carboplatin interferes with the development of the genetic material in a cell, the DNA. This stops it from dividing into 2 new cells and kills it. Carboplatin is a chemotherapy treatment for many different types of cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/carboplatin)
Mechanisms of Action: DNA Synthesis Inhibitor,Mitosis Inhibitor,Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Bosnia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Malaysia, Mexico, Moldova, Montenegro, Morocco, Netherlands, New Zealand, Norway, Panama, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Adenocarcinoma|Anal Cancer|Bladder Cancer|Breast Cancer|Carcinosarcoma|Cervical Cancer|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Diffuse Large B-Cell Lymphoma|Endometrial Cancer|Endometrioid Carcinoma|Esophageal Cancer|Fallopian Tube Cancer|Gastrointestinal Cancer|Glioblastoma|Glioma|Hodgkin Lymphoma|Inflammatory Breast Cancer|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Mesothelioma|Mixed Tumor, Mullerian|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Other|Ovarian Cancer|Pain Unspecified|Peritoneal Cancer|Prostate Cancer|Retinoblastoma|Serous Cystadenocarcinoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Unilateral Breast Cancer|Uterine Cancer
Phase 2: Adenoid Cystic Carcinoma|Anus Cancer|Brain Cancer|Carcinoma, Adenosquamous|Edema|Erythema|Gliosarcoma|Head and Neck Cancer|Laryngeal Cancer|Lip Cancer|Lung Cancer|Male Breast Cancer|Mouth Cancer|Neoplastic Cells, Circulating|Neuroendocrine Carcinoma|Oncology Unspecified|Oropharyngeal Cancer|Pancreatic Cancer|Penile Cancer|Penile Diseases|Salivary Gland Cancer|Sarcoma|Thymoma|Urogenital Cancer|Urologic Cancer
Phase 1: Epilepsy|Kidney Cancer|Kidney Diseases|Melanoma|Muscle Spasticity|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| RETINO2018 | P3 |
Recruiting |
Retinoblastoma |
2035-01-20 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| Glo-BNHL | P3 |
Recruiting |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2031-05-01 |
27% |
2024-11-27 |
Primary Endpoints|Treatments |
| 2018-003335-29 | P3 |
Active, not recruiting |
Other |
2029-10-15 |
2022-03-13 |
Treatments |
|
| TROPICAL-1 | P2 |
Not yet recruiting |
Non-Small-Cell Lung Cancer|Brain Cancer |
2028-07-31 |
12% |
2025-04-17 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
| Debio 0123-101 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2027-11-01 |
23% |
2025-05-31 |
|
| STUDY00026643 | P2 |
Not yet recruiting |
Sarcoma|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Breast Cancer |
2027-12-31 |
12% |
2025-05-16 |
Primary Endpoints |
| NCI-2022-01540 | P3 |
Recruiting |
Endometrioid Carcinoma|Endometrial Cancer|Clear Cell Sarcoma|Mixed Tumor, Mullerian|Serous Cystadenocarcinoma|Clear Cell Adenocarcinoma|Carcinosarcoma |
2027-10-31 |
2025-03-28 |
Patient Enrollment|Primary Endpoints|Treatments |
|
| kp-acs-2 | P3 |
Recruiting |
Pain Unspecified |
2027-08-31 |
2025-05-02 |
Treatments |
|
| FCN-159-010 | P3 |
Not yet recruiting |
Glioma |
2027-04-30 |
2025-06-05 |
Primary Endpoints|Treatments |
|
| ZAP-IT | P2 |
Recruiting |
Male Breast Cancer|Triple Negative Breast Cancer |
2027-03-01 |
12% |
2024-12-19 |
Primary Endpoints|Treatments|Trial Status |
| NRG-GY022 | P1 |
Recruiting |
Kidney Diseases|Kidney Cancer |
2027-02-06 |
2023-11-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| PRIAM | P2 |
Recruiting |
Urogenital Cancer|Squamous Cell Carcinoma|Urologic Cancer|Penile Cancer|Penile Diseases |
2026-10-14 |
40% |
2024-08-17 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| CHIMERA | P2 |
Recruiting |
Mesothelioma |
2026-03-01 |
12% |
2024-11-09 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| AK105-304 | P3 |
Active, not recruiting |
Nasopharyngeal Cancer |
2026-02-23 |
66% |
2025-04-15 |
Primary Endpoints|Treatments |
| RANT-GC Trial | P1 |
Not yet recruiting |
Esophageal Cancer|Gastrointestinal Cancer|Adenocarcinoma |
2026-02-01 |
2% |
2024-11-27 |
Primary Endpoints|Treatments |
| Artemis | P2 |
Recruiting |
Thymoma |
2025-12-31 |
12% |
2023-10-24 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| CHAMP | P2 |
Recruiting |
Neuroendocrine Carcinoma|Prostate Cancer |
2025-12-01 |
12% |
2024-11-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| HARMONIC | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Adenocarcinoma |
2025-12-01 |
12% |
2024-10-24 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
| NAUTICAL | P3 |
Recruiting |
Bladder Cancer|Transitional Cell Carcinoma |
2025-12-01 |
2024-03-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| NCT04643379 | P2 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2025-11-30 |
12% |
2023-11-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| NCI-2017-00619 | P2 |
Active, not recruiting |
Edema|Breast Cancer|Erythema |
2025-10-31 |
12% |
2025-05-17 |
Primary Endpoints |
| NCI-2021-10907 | P2 |
Recruiting |
Lung Cancer |
2025-10-20 |
12% |
2023-09-22 |
|
| BARCODE2 | P2 |
Recruiting |
Prostate Cancer |
2025-09-30 |
2024-10-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
| AK104-307 | P3 |
Not yet recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2025-08-05 |
36% |
2023-08-15 |
Primary Endpoints|Treatments |
| NCT03245892 | P1 |
Active, not recruiting |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2025-08-01 |
23% |
2023-09-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |